Showing results (351-360 of 476) with videos related to
Sort By:
Pageof 48
Cancer Treatment Reports|April 1, 1985
Phase I trial of mitoxantrone in childrenR S Ungerleider, C B Pratt, T J Vietti, et al.Cancer Research|March 1, 1987
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapyM P Goren, R K Wright, C B Pratt, et al.Medical and Pediatric Oncology|January 1, 1991
Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugsW E Evans, J H Rodman, M V Relling, et al.Pediatric Hematology and Oncology|September 1, 1994
Outcome for patients with constitutional 13q chromosomal abnormalities and retinoblastomaC B Pratt, S C Raimondi, S C Kaste, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1984
The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexateW R Crom, C B Pratt, A A Green, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 15, 2010
Nasopharyngeal colonization by Neisseria lactamica and induction of protective immunity against Neisseria meningitidisCariad M Evans, Catherine B Pratt, Mary Matheson, et al.Cancer|March 15, 1992
Carcinoembryonic antigen and carbohydrate 19-9 antigen as markers for colorectal carcinoma in children and adolescentsC A Angel, C B Pratt, B N Rao, et al.The Journal of Biological Chemistry|May 18, 2004
Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocationPatrick J M Murphy, Mario D Galigniana, Yoshihiro Morishima, et al.Medical and Pediatric Oncology|April 1, 1996
Role of irradiation in management of synovial sarcoma: St. Jude Children's Research Hospital experienceJ Fontanesi, A S Pappo, D M Parham, et al.Biochemistry|November 13, 2002
Binding of hsp90-associated immunophilins to cytoplasmic dynein: direct binding and in vivo evidence that the peptidylprolyl isomerase domain is a dynein interaction domainMario D Galigniana, Jennifer M Harrell, Patrick J M Murphy, et al.Pageof 48